Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $52.
October 30, 2024 | 9:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences and maintained a price target of $52, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $52 price target by Needham suggests a positive outlook for Harmony Biosciences. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100